IQWiG Market Share Analysis for May 2026

Sie finden hier einige Fragen und Antworten zum Formblatt Interessenkonflikt.

Health > Public Health and Safety

Domainiqwig.de

Year Founded2004

Employees201 - 500

Annual Revenue$10M - $15M

IQWiG

IQWiG (including company regionals)

iqwig.de

See more website traffic and engagement information

IQWiG Revenue up to May 2026 is 10M - 15M

revenue generated by IQWiG top domains

IQWiG top domains revenue over 3 years

Revenue for IQWiG top domains

iqwig.de10M - 15M

See more with Sales Intelligence

Total visits to IQWiG's top domains

Understand IQWiG market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

iqwig.de39.2K

See more with Sales Intelligence

Avg. visit duration in IQWiG's top domains

Analyze IQWiG engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

iqwig.de00:00:29

See more with Sales Intelligence

Avg. pageviews on IQWiG's top domains

See how IQWiG keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

iqwig.de1.52

See more with Sales Intelligence

IQWiG top competitors by domain

Top similar sites in May 2026, ranked by their affinity

cochrane.deCompany NameCochraneEmployees51 - 200HQUnited Kingdom, LondonAnnual revenue$25M - $50MTotal visits18.8KHealth > Public Health and Safety

Top technologies used by IQWiG

These are the website technologies, by industry, used by IQWiG top domains

Payment & Currencies (24)

PayPal

Advertising (2)

Google Adsense

Conversion & Analytics (2)

Facebook Domain Insights

eCommerce (2)

Magento/Adobe Commerce

More Technologies

6

See all

News & Signals from IQWiG

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsIqwig is developing scientific concept for CAR-T cell therapies for the treatment of hemo-oncological diseases.To start, IQWiG is developing a scientific concept for CAR-T cell therapies for the treatment of hemo-oncological diseases (including leukemia), which will be compared to existing therapy alternatives.